Seattle Genetics CEO Makes the Case for a $100K Cancer Drug
Summary
I came out in support of the six-figure price tag for the Seattle Genetics drug in today’s BioBeat column.Over at Pharmalot, veteran industry writer Ed Silverman is polling readers about whether this is an appropriate price.Brett Chase over at Minyanville notes that the price may make some investors nervous about Seattle Genetics running into trouble with insurers, like Dendreon (NASDAQ: DNDN).CEO Clay Siegall had to see all the questions coming about price, and naturally, this was a main theme the folks at CNBC asked him about when he appeared on the financial TV network this morning.And if you’ve got your own views on the price of this new product, please leave a comment on this story below, or send me a note at ltimmerman@xconomy.com
Classifications
industries
Fintech & Banking
applications
Accounting and Taxes
AskAI Classifications
Labels
Content Marketing Software
SaaS
Web Analytics
Linked Companies
Shareaholic
$1M to $5M